Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals. Telix’s extensive pipeline for urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning is ...

Telix Completes Acquisition of FAP-targeting Theranostic Candidates. ASX, News, Telix today announces that it has completed the transaction to expand its theranostic pipeline with new candidates targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in… Read more

Telix is focused on developing therapies for urologic (prostate and kidney), neurologic (brain) and musculoskeletal (sarcoma) cancers. The Precision Medicine unit support the Therapeutics unit by enabling the delivery of personalised theranostic solutions to market using Telix’s diagnostics.

Telix is developing targeted radiation therapies with the potential to be efficacious as stand-alone treatments or as complements to existing treatment modalities, addressing areas of high unmet medical need. We pair each therapeutic with a diagnostic imaging agent.

At Telix we believe that everyone counts, we strive to be extraordinary, and we pursue our goals with determination and integrity every day

Telix will leverage RLS’ 31 licensed radiopharmacies located in major metropolitan areas across the U.S. to build a radiometal production and distribution network for key therapeutic and diagnostic isotopes alongside last-mile delivery of finished unit doses in relevant markets.

Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals.

Telix is actively exploring partnership opportunities for our programs and platforms. Please contact us to find out more..

Telix is pushing the frontiers of diagnostic and therapeutic nuclear medicine through a number of clinical trials, both company-sponsored and in collaboration with leading cancer centres around the globe. See below list of Telix trials that are currently active.

2025年1月13日 · Strong sales of Illuccix have led Telix to close out the year with revenue above guidance, while significantly progressing our strategic priorities. Boosting our balance sheet and the Nasdaq listing were major corporate milestones.